Estrella Immunopharma Warrant
ESLAW
11 hedge funds and large institutions have $212K invested in Estrella Immunopharma Warrant in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 5 reducing their positions, and 10 closing their positions.
42% less funds holding
Funds holding: 19 → 11 (-8)
80% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 10
91% less capital invested
Capital invested by funds: $2.24M → $212K (-$2.03M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$4.73K |
| 2 |
MFG
Magnus Financial Group
New York
|
+$2.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
-$2.19M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$9.82K |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$4.78K |
| 4 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
-$3.36K |
| 5 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$2.62K |
ESLAW Hedge Fund Activity: Q3 2023 in Review
11 of the 6,312 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma Warrant (ESLAW) for Q3 2023, worth a combined $212K — down 91% from $2.24M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ESLAW and 2 opened new positions — a net loss of 8 holders — while 5 trimmed existing stakes and 0 added.
The largest buyer was Cowen and Company, opening a new position worth an estimated $4.73K. The largest seller was Boothbay Fund Management, exiting entirely with an estimated $2.19M sold.
- 11 institutional investors held Estrella Immunopharma Warrant (ESLAW) as of Q3 2023, down from 19 in Q2 2023.
- Funds reported $212K of Estrella Immunopharma Warrant stock for Q3 2023, down 91% quarter-over-quarter.
- 2 funds opened new Estrella Immunopharma Warrant positions in Q3 2023 and 10 closed out, a net change of -8 holders.
- The largest Estrella Immunopharma Warrant buyer in Q3 2023 was Cowen and Company, an estimated $4.73K added.
- The largest Estrella Immunopharma Warrant seller in Q3 2023 was Boothbay Fund Management, an estimated $2.19M sold.
Based on aggregated 13F filings for Q3 2023.